As a result of neuro-vascular coupling, the functional effects of antipsychotics in human brain have been investigated in both healthy and clinical populations using haemodynamic markers such as regional Cerebral Blood Flow (rCBF). However, the relationship between observed haemodynamic effects and the pharmacological action of these drugs has not been fully established. Here, we analysed MRI-based rCBF data from a placebo-controlled study in healthy volunteers, who received a single dose of three different D2 receptor antagonists and tested the association of the main effects of the drugs on rCBF against normative population maps of D 2 R protein density and gene-expression data. In particular, we correlated CBF changes after antipsychotic administration with non-displaceable binding potential (BP ND ) template maps of the high affinity D 2 -antagonist Positron Emission Tomography (PET) ligand [ 18 F]Fallypride and brain post-mortem microarray mRNA expression data for the DRD2 gene. For all antipsychotics, rCBF changes were directly proportional to brain D 2 R densities and DRD2 mRNA expression measures, although PET BP ND spatial profiles explained more variance as compared with mRNA profiles (PET R 2 range= 0.20-0.60, mRNA PET R 2 range 0.04-0.20, pairwise-comparisons all p<0.05). In addition, the spatial coupling between ∆CBF and D 2 R profiles varied between the different antipsychotics tested, possibly reflecting differential affinities. Overall, these results indicate that the functional effects of antipsychotics as measured with rCBF are tightly correlated with the distribution of their target receptors in striatal and extra-striatal regions. Our results further demonstrate the link between neurotransmitter targets and haemodynamic changes reinforcing rCBF as a robust in-vivo marker of drug effects. This work is important in bridging the gap between pharmacokinetic and pharmacodynamics of novel and existing compounds.
Introduction
Antipsychotics are still the preferred choice for the treatment of conditions such as schizophrenia and other mental health disorders with psychotic features (Stroup et al, 2009 ).
The main target of most of these compounds is the dopamine D 2 receptor (D 2 R) (Burt et al, 1977; Farde et al, 1986) where they act as antagonists or partial agonists. D 2 R occupancy of antipsychotics has been assessed in vivo with emission tomography in healthy controls and clinical populations (Agid et al, 2007; Kapur et al, 1995; Nyberg et al, 1995) and it has also been linked with treatment response (Kapur et al, 2000) . While antipsychotics have been well characterized in terms of their pharmacokinetics (PK) and clinical response, their impact on brain physiology and function is still not well understood. A deeper understanding of these effects is crucial to uncover biological mechanisms driving their clinical efficacy as well as their side effects.
Functional effects of antipsychotics in the brain have been investigated using different neuroimaging tools. Seminal work using Positron Emission Tomography (PET) [ 18 F]fluorodeoxyglucose and [ 15 O]H 2 O showed that drug naïve first episode psychosis patients, had increased glucose utilization after treatment with antipsychotics (DeLisi et al, 1985; Holcomb et al, 1996) and greater perfusion (Goozee et al, 2014; Miller et al, 1997; in the basal ganglia. Similar results were also obtained in healthy volunteers using a single dose of antipsychotics (Kim et al, 2013; Mehta, 2003) . Studies using Arterial Spin Labelling (ASL), a Magnetic Resonance Imaging (MRI) sequence designed to quantitatively measure regional cerebral blood flow (rCBF), found results in line with the earlier PET studies. In particular, (Fernández-Seara et al, 2011) reported increased rCBF in the striatum and thalamus in healthy volunteers after a single oral dose of 10 mg of metoclopramide (a D 2 R antagonist) and (Handley et al, 2013) showed that both haloperidol 3 mg (a D 2 R antagonist) and aripiprazole 10 mg (a D 2 R partial agonist with 5-HT2a antagonism properties) increased rCBF in the striatum in healthy volunteers with a larger effect size for haloperidol. Recently, we tested the effects of a single clinical effective dose of different antipsychotics . Consistent with the existing literature, 3 mg haloperidol, 2 mg risperidone and 0.5 mg risperidone increased striatal rCBF as compared with placebo.
One of the major limitations of pharmacological MRI studies stands on the haemodynamic nature of the main functional measures (e.g. BOLD and rCBF). According to the neurovascular coupling model (Attwell and Iadecola, 2002; Logothetis et al, 2001) changes in haemodynamic MRI measures reflect a complex cascade of cellular, metabolic and vascular events associated with changes in neuronal activity (Heeger and Ress, 2002; Hoge et al, 1999; Singh, 2012) . In line with this model, the main effects of drug may be interpreted as the result of dose-dependent enhanced or reduced pre-or post-synaptic activity due to the action of the drug on its targets (Khalili-Mahani et al, 2017) . Although many antipsychotics bind to numerous receptors, the effects on rCBF have been tacitly attributed to D 2 R blockade. In particular, D 2 R antagonism would lead to enhanced neurotransmitter turnover in the dopaminergic synapses inducing metabolic activity and therefore perfusion demands (Goozee et al, 2014; Handley et al, 2013) . The findings of altered dopamine synthesis capacity after acute antipsychotics administration in human volunteers and rats support this hypothesis (Hertel et al, 1996; Ito et al, 2009; Vernaleken et al, 2008) . However, since MRI does not measure neuronal activity directly, making a link between neuro-receptor binding and haemodynamic effects of these compounds requires a degree of conjecture. In addition, in the case of dopaminergic drugs, MRI hemodynamic changes have also been related to non-neuronal mechanisms including the action of D 1 -like receptors on vessels and D 2 -like receptors on perivascular astrocytes (Choi et al, 2006; Krimer et al, 1998) . For these reasons, despite the body of evidence, the neurochemical mechanisms underlying CBF changes after antipsychotics administration remain unclear. The use of multimodal approaches, e.g. combining MR measures with ex-vivo autoradiography , have started to fill this gap of knowledge.
Receptor occupancy theory posits that the magnitude of the drug response is a function of receptor availability (Clark, 1970; Ploeger et al, 2009) . In other words, incremental changes in functional response correspond to increments of the fraction of receptors bound. This relationship also depends on specific characteristics of each compound, such as receptor affinity (i.e. K i ). This basic pharmacology principle has been used to characterize the spatial profile of drug effects in the brain (also called "drug fingerprinting") assuming that brain regions with high density of the target receptor will show higher magnitude of drug effects (Khalili-Mahani et al, 2017) . This approach has been proposed to describe MRI changes to dopaminergic drugs in preclinical data (Mandeville et al, 2013) . Indeed, a monotonic increase in rCBF has been observed following injection of an increasing dose of the D 2 /D 3 antagonist radiotracer [ 11 C]raclopride in the striatum of two male rhesus macaques .
Interestingly, [ 11 C]raclopride non-displaceable binding potential changes (BP ND ) reflecting changes in D 2 /D 3 receptor occupancy, correlated with the amplitude of hemodynamic changes (i.e. rCBF): the higher the dose the larger rCBF increase; and in time: BP ND variation and changes in rCBF showed similar temporal profiles. The same group also found an inverse relationship between receptor occupancy and rCBF with the selective D 2 /D 3 agonist quinpirole in male rhesus macaques (i.e. rCBF decrease in face of dose-dependent increase of receptor occupancy) (Sander et al, 2016a) . Both studies provide evidence for a neurovascular coupling mechanism linking MR haemodynamic changes and D 2 /D 3 receptors pharmacological modulation in non-human primates although they are limited to the striatal region.
The aim of the present work is to test in humans whether rCBF changes induced by a single dose of different antipsychotics co-varies with in vivo measures of D 2 R distribution. In particular, we employed two datasets from healthy volunteers to evaluate the spatial correlation between rCBF variation in the placebo vs antipsychotic comparison against the population-based receptor density profiles derived from human PET scans using the high affinity D 2 /D 3 antagonist [ 18 F]Fallypride (Mukherjee et al, 1995) . We also investigated the same relationship at the gene expression level using post-mortem mRNA expression measures of DRD2 (the gene coding for D 2 R) extracted from the Human Allen Brain Atlas (ABA) (Hawrylycz et al, 2012a) . Brain mRNA expression variation across brain regions has been shown to be associated with resting state fMRI networks suggesting that brain hemodynamic response may be linked to the architecture of the human brain transcriptome (Hawrylycz et al, 2015; Richiardi et al, 2015) . Here, brain microarray mRNA expression data was chosen as a proxy to protein-level receptor density in the human brain. In fact, while post-transcriptional events may alter the relationship between gene expression and protein synthesis (Liu et al, 2016) , brain mRNA expression maps have been shown to predict in vivo proteins level as measured with PET (Beliveau et al, 2017; Rizzo et al, 2014) .
Following the receptor occupancy theory and the neurovascular coupling model proposed by we hypothesized that there will be a detectable linear relationship between main effects of antipsychotics on CBF measures and D 2 R receptor density profiles evaluated at the protein and gene expression level. Even though brain microarray mRNA expression data from the ABA is noisier and more discrete (i.e. limited number of samples) than the PET BP ND maps, we expect CBF increases after antipsychotics to be linearly associated also with DRD2 mRNA expression spatial profiles. However, given the fact that mRNA expression only approximates cellular protein levels due to post-transcriptional regulatory mechanisms we predict microarray data to explain less variance in CBF changes than PET derived maps.
Materials and Methods

Participants and study design
Data were collected as part of a project approved by the National Research Ethics Service Committee London -Brent (REC reference: 13/LO/1183). Details about participants, protocol and study design have been described in detail in . Briefly, forty-two healthy male subjects were enrolled in a double-blind, placebo-controlled, randomised, fully counterbalanced, three-session crossover design. Participants were randomised into two equal parallel study groups (Group 1 age mean/SD 27.6/6.9; Group 2 age mean/SD 28.3/6.3). In the first group participants received placebo, 7.5 mg of olanzapine (OLA), or 3 mg of haloperidol (HAL) on each study day. In the second group, participants received placebo, 0.5 or 2 mg risperidone (lowRIS and highRIS respectively). All but lowRIS dosage were chosen in order to achieve on average at least 60% of D2 receptor occupancy (Kapur et al, 2000; Tauscher et al, 2004) . On dosing day, participants followed a standardised regime. The MRI scan was performed at the time of predicted peak level of plasma concentration of the drug after oral administration (T max ): approximately 5 hours after drug administration for Group 1 and 2 hours for Group 2 (de Greef et al., 2011; Midha et al., 1989; Nyberg et al., 1997; Tauscher et al., 2002) . Study days were seven days apart to allow washout between sessions. After the final visit, a follow-up phone call was made to monitor potential adverse events related to the study drugs.
MRI acquisition and pre-processing
All scans were conducted on a GE MR750 3 Tesla scanner using a 12-channel head coil.
ASL image data were acquired using a 3D pseudo-continuous ASL sequence (3DpCASL) with a multi-shot, segmented 3D stack of axial spirals (8-arms) readout with a resultant spatial resolution (after re-gridding and Fourier Transformation) of 2x2x3mm. Four controllabel pairs were used to derive a perfusion weighted difference image. The labelling RF pulse had a duration of 1.5s and a post-labelling delay of 1.5s. The sequence included background suppression for optimum reduction of the static tissue signal. A proton density image was acquired in 48s using the same acquisition parameters in order to compute the CBF map in standard physiological units (ml blood/100g tissue/min). Pre-processing of all CBF data was performed exactly as described in Hawkins et al, (2018) (for further details please see Supplementary Materials). Figure 1 shows the general framework of the analysis. D 2 R profiles where extracted from an independent [ 18 F]Fallypride PET template obtained by averaging six binding potential (BP ND ) whole brain maps acquired in healthy young volunteers (age range: 18-30 years) who did not participate in the drug study (Dunn et al, 2009 ). [ 18 F]Fallypride is a D 2 /D 3 receptor antagonist and it is a well-established PET radiotracer in the study of D 2 -like receptor distribution in the brain (Mukherjee et al, 1995) . Compared with other D 2 -like antagonist radiotracers (e.g. [ 11 C]raclopride), [ 18 F]Fallypride has higher affinity and higher signal-tonoise ratios in vivo and therefore provides reliable quantitative measures of D 2 R concentration including extra-striatal brain regions (Mukherjee et al, 2002; Stark et al, 2018) .
Receptor density profiles
The [ 18 F]Fallypride template was segmented with the Desikan-Killiany Atlas (Desikan et al, 2006) and for each of the 85 Regions of Interest (ROIs) of the template, the voxel-wise mean BP ND value was extracted with the flslmeants function implemented in the Functional Software Library suite (FSL, FMRIB, Oxford, UK). Conventional parametric modelling of regional BP ND was performed by using the cerebellum as reference region (Ichise et al, 2003) . Therefore, both left and right cerebellar ROIs (namely "rh_cerebellum_cortex" and "lh_cerebellum_cortex") were excluded from correlation analyses with CBF profiles. To compare the contribution of striatal vs extra-striatal regions to this association, we also extracted BP ND profiles from a [ 11 C]raclopride template obtained from a matchted group of healthy controls (Grecchi et al, 2014 ) (see Supplementary Material).
CBF profiles
CBF profiles were obtained from maps of CBF changes at the group level. In particular, for each antipsychotic, a group-wide paired T-test was performed in SPM12 for each drug vs placebo. Whole brain total blood flow was added as a covariate of no interest in the model to account for peripheral (global) drug effects and between-subjects variability in global brain perfusion (Handley et al, 2013; Viviani et al, 2009; . In agreement with previous studies (Handley et al, 2013; Hawkins et al, 2018) , we identified statistically significant increases in CBF after drug administration (against placebo) and have thus focussed on this contrast in the remainder of this work. Therefore, DRUG>PLACEBO contrast maps for each antipsychotic where segmented by using the Desikan-Killiany Atlas (Desikan et al, 2006) using the same approach used for the extraction of receptor profiles. This resulted in 85 ∆CBF profiles measuring the antipsychotic induced increase of CBF in each ROI. For consistency with the receptor profile data, we carried out correlation analyses excluding the two cerebellum ROIs.
Statistical analysis for the ∆CBF/receptor density profiles correlations
To test the associations between ∆CBF profiles (derived for each antipsychotic) and D 2 /D 3 receptor density profiles, linear regression models as implemented in SPSS were used (IBM, SPSS Statistics, Version 23). Normal distribution of the residuals of the regression models were tested by Shapiro-Wilk test. BP ND data were transformed using a natural logarithmic function (ln) so that the residuals conformed to a normal distribution. For all linear regression models Mahalanobis distance and Cook's distance were computed in order to explore the presence of multivariate outliers and estimate the presence of highly influential data points.
To identify multivariate outliers, Mahalanobis distance values were compared to a chi-square distribution with degrees of freedom equal to the number of variables (two in this case) with p= 0.001 (Finch, 2012; Tabachnick and Fidell, 2013) . Any data point with Cook's distance higher than 1 was considered as highly influential outlier and excluded from the analysis (Cook and Weisberg, 1982) . Non-parametric Spearman's correlations between ∆CBF profiles and receptor BP ND profiles were also performed as a countercheck. In addition, Fisher's r-toz transformation was performed to test pairwise significance of the difference between correlation coefficients of ∆CBF profiles between different antipsychotics. Asymptotic covariance method was adopted to account for the fact that correlations had one variable in common (Lee and Preacher, 2013) mRNA profiles and genetic correlations DRD2 gene brain microarray mRNA expression values were extracted from ABA data (http://human.brain-map.org) by using the Multimodal Environment for Neuroimaging and Genomic Analysis (MENGA) toolbox (http://www.nitrc.org/projects/menga/) (Rizzo et al, 2016) . The same toolbox was used to carry out correlations with ∆CBF profiles of each antipsychotic. First, antipsychotics' contrast images (DRUG>PLACEBO) were resampled in the ABA space. Then, each CBF image sample was spatially matched with the corresponding genomic ABA sample within a search window of a sphere of 5mm radius centred on the MNI coordinates of the ABA sample. Both CBF contrast image and ABA data were then segmented using the list of structures (N= 169) provided by the ABA (Hawrylycz et al, 2012b) . A subset of 89 structures (ROIs), each containing at least one genomic sample for all the six ABA brains (donors), was selected to perform correlations between ∆CBF profiles and gene expression. After completing the matching and the extraction of ∆CBF and gene expression profiles, two different correlations were performed: 1) between-donors correlation or gene auto-correlation returning the biological variability of the spatial profile of mRNA expression between donors (the higher the gene autocorrelation the lower the heterogeneity in mRNA expression spatial profile between donors); 2) correlation between each gene expression and the ∆CBF by ROIs also called cross-correlation. A Principal Component Analysis (PCA) on mRNA expression measures of the 6 ABA donors was performed beforehand in order to extract the component that accounted at least for the 95% of the total variance in the mRNA expression data. In particular, the PCA was performed on an 89x6 matrix (89 ROIs by 6 donors) and represented a consistent spatial mRNA expression profile across all donors. This component was then used in the regression model against CBF profiles. Significance was assessed with a bootstrapping approach resulting in a chance likelihood of the correlation coefficient expressed as a %. More specifically, ROIs were permuted within donors repeating the correlation between PCA component and CBF profiles 1,000 times, in order to obtain a measure of the likelihood that the correlation found was different from chance level. A multivariate spatial correlation using MENGA was also performed between DRD2 gene expression profiles and [ 18 F]Fallypride BP ND maps. As for protein density profile analysis, Fisher's r-to-z transformation was performed to test pairwise significance of the difference between correlation coefficients of ∆CBF profiles between different antipsychotics and also between PET and mRNA profiles.
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Results
CBF changes with D 2 receptor profiles correlations
All antipsychotic ∆CBF profiles significantly correlated with [ 18 F]Fallypride BP ND template values (Table 1 and (McCormick et al, 2010) , with the stronger the association between ∆CBF profiles and D 2 receptor densities the lower the Ki (Table 1 and Figure S2 ). In the pairwise correlation comparisons we found significant difference for HAL vs OLA (z= 5.46), lowRIS vs OLA (z= 4.19) and vs highRIS vs OLA (z= 3.90) (all p two-tailed < 0.01, Bonferroni corrected, Figure S2 ). All the other comparisons were not significant. To compare striatal vs extra-striatal contributions to this association we also performed correlations between ∆CBF and receptor density profiles by extracting BP ND values from a [ 11 C]raclopride PET template.
We found weaker correlation with [ 11 C]raclopride BP ND as compared with [ 18 F]Fallypride BP ND (see Supplementary Material).
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[ Figure 2 about here]
mRNA expression correlations
The average correlation coefficient (R 2 ) of the genomic autocorrelation analysis for the DRD2 gene was 0.575 (standard deviation= 0.058) for the six donors. This result indicated good stability between donors of DRD2 mRNA expression spatial profile (Rizzo et al, 2016) .
For the different antipsychotic drugs, the correlation coefficients were all positive and statistically significant ( Figure 3 and Table 1 ) and also significantly lower than those obtained for the PET template (PET R 2 range= 0.20-0.60; mRNA PET R 2 range 0.04-0.20; pairwise-comparisons all p<0.05). As for the correlation with [ 18 F]Fallypride values, genomic mRNA expression correlations qualitatively mirrored Ki differences (McCormick et al, 2010) between antipsychotics at D 2 R ( Figure S2 ). However, none of the pairwise comparisons between correlation coefficients between antipsychotics were statistically significant after correction for multiple comparisons.
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Discussion
The aim of the present study was to investigate the relationship between the effects of single clinical effective doses of antipsychotics on rCBF and receptor distribution profiles in the brain as indexed by [ 18 F]Fallypride BP ND values and brain DRD2 mRNA expression profiles.
Consistently with our hypothesis, we found that for all compounds there was a spatial coupling between drug-induced CBF changes and D 2 receptor density profiles (at both protein and gene expression level). In addition, we found that mRNA data explained less variance in CBF changes than PET derived map.
Receptor density profiles
The association between CBF changes induced by all antipsychotics and receptor brain spatial distribution of D 2 R matches earlier evidence in non-human primates showing large CBF increases after injection of the D 2 antagonist PET tracer [ 11 C]raclopride in brain regions with high D 2 R density . This suggests that the relationship between the physiological response to D 2 R antagonist and D 2 R availability described by in preclinical models also exists in vivo in humans. Furthermore, we have shown that the relationship between ASL-CBF increases after antipsychotic administration also matched [ 18 F]Fallypride BP ND values in extra-striatal ROIs significantly populated by D 2 R such as the thalamus and the amygdala, even though they show lower BP ND values as compared with striatal ROIs. These results extend earlier evidence and suggest that the linear coupling between CBF response to dopaminergic drugs and D 2 R concentration might also be a valid model outside the striatum. This interpretation is also supported by the weaker correlation of ∆CBF with [ 11 C]raclopride BP ND as compared with [ 18 F]Fallypride BP ND (Supplementary Material).
Microarray mRNA expression data
We found that for all antipsychotics, the ∆CBF profiles also correlated with microarray mRNA expression data extracted from the ABA. All genomic correlations were positive and therefore in the same direction of [ 18 F]Fallypride BP ND linear models. Notably, microarray mRNA expression measures explained less variance in ∆CBF than [ 18 F]Fallypride BP ND values. This is consistent with our hypothesis motivated by the existence of a large variability between mRNA expression and protein synthesis due to post-transcriptional regulation mechanisms (Liu et al, 2016) . Our findings are consistent with previous works that have linked the spatial architecture of the brain transcriptome to brain structure (Grecchi et al, 2017; Veronese et al, 2015) , function (Hawrylycz et al, 2015; Richiardi et al, 2015) and in vivo measures of brain proteins (Gryglewski et al, 2018; Rizzo et al, 2014; Veronese et al, 2016a) . Here we could show that post mortem brain mRNA expression data may potentially be used to map also variations in MRI-based functional response to drug stimulation. However, such mapping has still many limitations to be addressed in order to adopt it extensively in the context of pharmacological-MRI studies. For instance, it might be difficult to use mRNA expression mapping in neurotransmitter systems where protein synthesis is highly dependent on post-transcriptional regulation mechanisms (e.g. serotonin system) (Beliveau et al, 2017; Rizzo et al, 2014) . While further studies are needed to fully validate this mRNA expression-MRI approach, it might be especially valuable for profiling the functional effects of drugs with poorly characterized or unknown targets. Interestingly, as for the correlation with receptor density profiles, the rank order of correlations between ∆CBF and DRD2 mRNA expression measures mirrored affinity profiles of the compounds, although these differences were only numerical. It is worth noting that the variance explained by genomic correlation was lower than the PET correlations (Table 1) , which might have reduced the chance of detecting any significant difference on the pairwise comparison between the correlation coefficients.
These findings represent a further evidence supporting the hypothesized PK/PD model of antipsychotic effect of CBF measures (Mandeville et al, 2013; Sander et al, 2013 ). Indeed, we were able to show that quantitative measures of brain functional effect of antipsychotics (i.e. CBF changes) are directly associated with receptor density measures evaluated at different scales: mRNA expression and protein density.
Differential strength of association between ∆CBF and receptor density profiles.
The correlation strength between ∆CBF and receptor density measured with PET varied between the different antipsychotics tested. One possible interpretation of this difference might be related to the differential affinities for these compounds to D 2 R .
Our data seems to be in line with this hypothesis. In fact, the strengths of the association were higher for antipsychotics with higher affinity for D 2 R (Table 1 and Figure S1 ). In particular, HAL was the drug with the highest correlation coefficient and the lowest Ki, whereas OLA showed the lowest correlation coefficient and the highest Ki. Both lowRIS and highRIS were in the middle between HAL and OLA. Another possible interpretation might be that related with the different secondary affinities between the drugs. For instance, for compounds with an high affinity with 5HT2a receptors like risperidone and olanzapine, part of the effect on CBF might also be linked with a mechanism different from D 2 R blockade (Goozee et al, 2014) . Nonetheless, differences in brain disposition of antipsychotics have been reported in previous studies (Kornhuber et al, 2006; Rodda et al, 2006) . In particular, animal data suggested that antipsychotics (including the ones considered in the present work) show different blood-brain barrier penetration and brain clearance leading to dissimilar spatial distribution in the brain (Loryan et al, 2016) . Even though these dissimilarities have been reported to be only moderate (Loryan et al, 2016) , brain disposition is a factor to be considered in addition to receptor affinity when linking the pharmacodynamics of each antipsychotic with receptor occupancy. Therefore, without maps of brain deposition variation, conclusions regarding the D 2 R affinities and strength of associations between receptors and CBF are necessarily incomplete.
Limitations
A number of limitations need to be considered for the present study. First, we used population-based profiles of D 2 R density as the spatial architecture of D 2 R is typically consistent across individuals (Rizzo et al, 2014; Veronese et al, 2016b) . For example, the striatum always has higher D 2 R density than the thalamus which in turn has higher D 2 R density than the cortex. However, variance in density between individuals within the same brain region may drive inter-individual differences in the drug functional response. Individualized receptor profiles mapping is therefore necessary to bring more precision to the method and to further validate the present findings. Nevertheless, normative atlases for protein and mRNA expressions have proven useful in many different applications, suggesting that the core spatial architecture of the brain receptor systems is consistent across individuals (Beliveau et al, 2017; Rizzo et al, 2014; Veronese et al, 2016b) .
In addition, we considered only local effects by matching CBF changes and D 2 R receptor density measures with the same ROIs. However, studies in patients and healthy volunteers showed that antipsychotics also produce changes in functional connectivity in rs-fMRI suggesting the existence of downstream effects (Cole et al, 2013; Sarpal et al, 2015) that were not included in our analyses.
As discussed above, increases in CBF after acute antipsychotic challenge have been usually interpreted as the result of a neuronal metabolic changes due to D 2 R blockade. However, D 2 Rs are also present in perivascular astrocytes modulating brain hemodynamic changes (Choi et al, 2006) . In addition, both risperidone and olanzapine, but not haloperidol, act as antagonists at the serotonin-2a receptors (5HT2a) (Meltzer, 1999) . Blockade of 5HT2a receptors on smooth-muscle cells of brain arteries has been shown to induce relative vasodilation in animal models (i.e. blocking vasoconstriction caused by the endogenous ligand serotonin) (Kovács et al, 2012) . Therefore, the degree to which these non-neuronal effects contribute to the associations described here is not known.
Conclusion
Understanding the link between neurochemical changes and brain function is crucial to uncover mechanisms underlining the effects of psychopharmacological treatment and between-subjects variability in response. In this work we investigated the case of antipsychotics whose functional effect, evaluated as changes in CBF measures, mirror the well-known spatial distributions of their main target (i.e. D 2 R). The characterisation of the haemodynamic response using this multimodal approach might be applicable also for other classes of drugs and it becomes particularly valuable for profiling compounds known to bind to multiple targets or with unknown or poorly characterised targets. Finally, our work demonstrates that the use of MRI 3D pCASL as a measure of regional CBF offers an efficient, non-invasive tool to investigate CNS penetration in the process of psychotropic drug development that is also linked with brain chemistry.
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